Key result
Admission hyperkalemia is linked to ~81% higher in-hospital mortality in hospitalized heart failure patients.
Why the study?
Dyskalemias are common and associated with adverse outcomes in HF, but evidence regarding their association with in-hospital mortality in the Americas, particularly Latin America and the Caribbean, remains limited.
Does admission dyskalemia (hypokalemia or hyperkalemia) increase the risk of all-cause in-hospital mortality compared to normokalemia in patients hospitalized for heart failure across the Americas?
Cohort (n=1,541)
Yes
Does admission dyskalemia (hypokalemia or hyperkalemia) increase the risk of all-cause in-hospital mortality compared to normokalemia in patients hospitalized for heart failure across the Americas?
Answers are grounded in this paper and cite their sources.
In a large multinational cohort across the Americas, admission hyperkalemia (≥5.0 mmol/L) in patients hospitalized for heart failure is independently associated with an 81% higher risk of in-hospital mortality, serving as an important marker of severe clinical vulnerability.
BACKGROUND: Heart failure (HF) is a major global health concern, and dyskalemias are common and associated with adverse outcomes. However, evidence from the Americas, particularly Latin America and the Caribbean, remains limited. OBJECTIVE: To evaluate the association between admission dyskalemias and in-hospital mortality in hospitalized patients with HF across the Americas. METHODS: This subanalysis of the AMERICCAASS Registry included hospitalized patients with HF with available admission serum potassium and documented discharge status. Patients were classified as hypokalemic (< 3.5 mmol/L), normokalemic (3.5-4.9 mmol/L), or hyperkalemic (≥ 5.0 mmol/L). In-hospital mortality was assessed using Poisson regression and propensity score overlap weighting. RESULTS: Among 1541 patients, 12.5% had hypokalemia, 75.6% normokalemia, and 11.9% hyperkalemia. Median age was 68 years, and 60.6% were male. Chronic kidney disease was more frequent in hyperkalemia (30.4%), whereas atrial fibrillation was more frequent in hypokalemia (30.7%). Dyskalemic patients more often presented with hypoperfusion profiles and higher New York Heart Association class. In the propensity score overlap-weighted analysis, hyperkalemia was associated with higher in-hospital mortality (aRR 1.81; 95% CI 1.10-2.97; p = 0.019), whereas no statistically significant association was detected for hypokalemia (aRR 1.43; 95% CI 0.79-2.60; p = 0.237). CONCLUSION: Admission hyperkalemia was associated with higher in-hospital mortality among hospitalized patients with HF across the Americas. Given the observational design, hyperkalemia should be interpreted primarily as a marker of greater disease severity and short-term clinical vulnerability rather than as a direct causal determinant of mortality.
No takes yet. Share an insight, caveat, or question.
Seni-Molina et al. (2026) conducted a cohort in Hospitalized heart failure (n=1,541). Admission hyperkalemia (serum potassium ≥ 5.0 mmol/L) and hypokalemia (< 3.5 mmol/L) vs. Normokalemia (serum potassium 3.5-4.9 mmol/L) was evaluated on All-cause in-hospital mortality (hyperkalemia vs normokalemia) (aRR 1.81, 95% CI 1.10-2.97, p=0.019). Admission hyperkalemia was associated with higher in-hospital mortality vs normokalemia in hospitalized heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: